anthonyyazdaniml/gliner-biomed-curated-corpus huggingface dataset:
The present invention provides compounds useful as agents for the prevention or treatment of a sex hormone-dependent disease or the like. That is, the present invention provides fused heterocyclic derivatives represented by the following general formula (I), pharmaceutical compositions containing the same, medicinal uses thereof and the like. In the formula (I), rings A is 5-membered cyclic unsaturated hydrocarbon or 5-membered heteroaryl; R A  is halogen, alkyl, alkenyl, alkynyl, carboxy, alkoxy, carbamoyl, alkylcarbamoyl, etc.; ring B is aryl or heteroaryl; R B  is halogen, alkyl, carboxy, alkoxy, carbamoyl, alkylcarbamoyl, etc.; E 1  and E 2  are oxygen atom, etc.; U is single bond or alkylene; X is a group represented by Y, -O-(alkylene)-Y or -O-Z (in which Y is Z or amino substituted by Z, etc.; Z is cycloalkyl, heterocycloalkyl, aryl, heteroaryl, etc.
This is a pilot study of 1 group of patients. The analysis of relaxin levels in serum and follicular fluid obtained on the day of puncture of the follicles in patients undergoing treatment in the IVF protocol is carried out.
The Quality improvement project(QIP) arm will perform QIP intervention. Patients in the QIP arm will be enrolled after about 3-month QIP intervention. The QIP interventions include: establish a coaching committee, quality improvement workshop, implementation of quality improvement measures, as well as evaluation periodically and feedback.
Diet will be distributed with 6 meals (breakfast, lunch, dinner and 3 snacks). This is the usual diet prescribed for women with GDM at the Department of Endocrinology and Nutrition of both Centers. Energy intake distribution: 25% breakfast, 5% snack, 30% lunch, 10% snack, 25% dinner and 5% snack.
After receiving standard gastrectomy with D2 lymphadenectomy, regular follow-up every 3 months alone. Abdomen/chest CT scan will be performed every 6 months after surgery.
We have discovered that growth hormones form ternary complexes with their receptors in which site 1 on the hormone first binds to one molecule of receptor and then hormone site 2 then binds to another molecule of receptor, thereby producing a 1:2 complex. We believe this phenomenon is shared by other ligands having similar conformational structure. Assays based on this phenomenon are useful for identifying ligand agonists and antagonists. Sites 1 and 2 are structurally identified to facilitate, generation of amino acid sequence variants of ternary complex-forming ligands. Novel variants of growth hormone, prolactin placental lactogen and other related ligands are provided. As a result of our studies with the ternary complex we have determined that selected antibodies to the receptor for these ligands are capable of acting as ligand agonists or antagonists. Novel growth hormones and novel uses for anti-growth hormone receptor antibodies are described. Methods for inhibiting the growth of breast cancer cells are also described.
A computer system for identifying code hierarchy bias in a medical priority dispatch system, computer system for identifying code hierarchy bias in a medical priority dispatch system is disclosed. Further disclosed are a computer-implemented method to improve the clinical accuracy of determinant level codes generated by medical priority dispatch systems; a computer-implemented method for generating codes based on caller responses to enable evaluation and research of code hierarchy bias in medical priority dispatch systems and a computer-implemented method for emergency medical dispatch response. The computer system for identifying code hierarchy bias in a medical priority dispatch system comprises a medical priority dispatch system and a code hierarchy system The medical priority dispatch system generates a determinant level code indicative of the criticality of the call based on caller responses to questions asked by a dispatcher. The questions are provided to the dispatcher according to a pre-scripted protocol by the medical priority dispatch system, and the responses report represents a plurality of aspects and the determinant level code represents a subset of the plurality of aspects. Each aspect of the plurality of aspects comprising one of the following: a sign, a symptom, a condition. The code hierarchy system is in communication with the medical priority dispatch system. The code hierarchy system is configured to receive the determinant level code generated on the medical priority dispatch system, to generate a determinant level sub-code based on a combination of signs, symptoms, and conditions reported in the caller responses to the questions asked by the dispatcher, to store the determinant level code and the determinant level sub-code pair; and communicate to an emergency response agency the determinant level code and determinant level sub-code. The determinant level sub-code represents the combination of reported signs, symptoms, and conditions. The computer system compares the determinant level code and determinant level sub-code pair to other determinant level code and determinant level sub-code pairs to identify whether a combination of reported aspects of a situation is susceptible to code hierarchy bias and outputs information resulting from the comparison of determinant level code and determinant level sub-code pairs that can be used to improve the clinical accuracy of the determinant level codes generated by the medical priority dispatch system.
Divalproex sodium delayed-release tablets were studied in seven pediatric clinical trials. 

Two of the pediatric studies were double-blinded placebo-controlled trials to evaluate the efficacy of divalproex sodium extended-release tablets for the indications of mania (150 patients aged 10 to 17 years, 76 of whom were on divalproex sodium extended-release tablets) and migraine (304 patients aged 12 to 17 years, 231 of whom were on divalproex sodium extended-release tablets). Efficacy was not established for either the treatment of migraine or the treatment of mania. The most common drug-related adverse reactions (reported > 5% and twice the rate of placebo) reported in the controlled pediatric mania study were nausea, upper abdominal pain, somnolence, increased ammonia, gastritis and rash. 

The remaining five trials were long-term safety studies. Two 6-month pediatric studies were conducted to evaluate the long-term safety of divalproex sodium extended-release tablets for the indication of mania (292 patients aged 10 to 17 years). Two 12-month pediatric studies were conducted to evaluate the long-term safety of divalproex sodium extended-release tablets for the indication of migraine (353 patients aged 12 to 17 years). One 12-month study was conducted to evaluate the safety of divalproex sodium delayed-release capsules in the indication of partial seizures (169 patients aged 3 to 10 years). 

In these seven clinical trials, the safety and tolerability of divalproex sodium delayed-release tablets in pediatric patients were shown to be comparable to those in adults [see Adverse Reactions (6)].
Group of 20 comparative patients PLWHIV without COVID-19. This group will realise only the interview of the research.
Synthesis of a thiacalixarene metal coordination compound and application of thiacalixarene metal coordination compound serving as an anti-cancer medicine belong to the field of medicines. The invention aims at compounding thiacalixarene and metals to form the thiacalixarene metal coordination compound which serves as a medicine to be applied in the anti-cancer aspect. Thiacalixarene sulfonate has good water solubility and a good complexing function with both soft metal ions and hard metal ions, and has the advantages of being good in chemical stability, modifiable in structure and the like. Metals of magnesium, copper, cobalt, manganese, zinc and nickel are necessary elements for human bodies, and the anti-cancer activity of compounds or coordination compounds of metals of cadmium and the like is already reported. Based on the causes, thiacalixarene sodium sulfonate is selected to serve as a ligand and react with metallic compounds of magnesium, copper, zinc, nickel, cadmium, lithium, cerium, manganese, rubidium, cobalt, thallium and the like, the thiacalixarene metal coordination compound is synthesized, and anti-cancer activity research is performed on the thiacalixarene metal coordination compound. The synthesis of the thiacalixarene metal coordination compound and the application of the thiacalixarene metal coordination compound serving as the anti-cancer medicine develop new fields for developing a novel anti-tumor medicine and functions of a third generation supramolecular compound calixarene, and has reference value, practical value and academic significance.
FIELD: medicine. ^ SUBSTANCE: invention relates to medicine, namely to surgery and disaster medicine, and can be used in case of necessity to stop hemorrhage caused by injury of parenchymatous organs in case of polytraumas. For this purpose at the stage of sorting out wounded people with symptoms of continuing intra-abdominal hemorrhage are detected, delivered to operation room, where in cause of taking anti-shock measures, intra-abdominal hemorrhage is diagnosed. After that, laparotomy is performed and source of hemorrhage is detected. On detected injuries of parenchymatous organs applied is hydrophilic powder two-component hemostatic preparation in form of mixture of synthetic zeolites of CaA and CaX types, synthesized in kaolin granules. CaA zeolites correspond to formula mCaOnNa2O2SiO2Al2O30.5H2O in volume amount within the interval 7080 wt %. CaX type zeolites correspond to formula mCaOnNa2O2.5SiO2Al2O30.5H2O in volume amount within the interval 3020 wt %. Crystal matrices of said zeolites contain calcium ions in quantity 810 wt %. After that, gauze tampon is applied and pressed by hand for 5-7 min until stable hemostasis is achieved. Simultaneously detection of other injuries is continued by revision of abdominal cavity organs which results in determination of further patient treatment tactics. ^ EFFECT: method makes it possible to ensure efficient stable primary hemostasis in case of multiple hemorrhages.
Idiopathic pulmonary fibrosis (IPF) is a progressive lung disease of unknown origin with limited treatment options and poor prognosis. The encouraging findings from preclinical investigations utilizing mesenchymal stem cells (MSCs) indicated that they could serve as a promising therapeutic alternative for managing chronic lung conditions, such as IPF. The objective of this study was to compare the efficiency of bone marrow-derived MSCs (BM-MSCs) versus prednisolone, the standard anti-inflammatory medication, in rats with bleomycin (BLM)-induced lung fibrosis. Four groups were created: a control group, a BLM group, a prednisolone-treated group, and a BM-MSCs-treated group. To induce lung fibrosis, 5 mg/kg of BLM was administered intratracheally. BLM significantly increased serum levels of pro-inflammatory cytokines and oxidative stress markers. The disturbed lung structure was also revealed by light and transmission electron microscopic studies. Upregulation in the immune expression of alpha-smooth muscle actin, transforming growth factor beta-1, and Bax was demonstrated. Interestingly, all findings significantly regressed on treatment with prednisolone and BM-MSCs. However, treatment with BM-MSCs showed better results than with prednisolone. In conclusion, BM-MSCs could be a promising approach for managing lung fibrosis.
<P>PROBLEM TO BE SOLVED: To provide new compositions of therapeutic cyclodextrin-containing polymeric compounds designed as a carrier for delivering small molecule therapeutics, and pharmaceutical compositions thereof.  <P>SOLUTION: The present invention relates to the new compositions of therapeutic cyclodextrin-containing polymeric compounds designed as a carrier for delivering small molecule therapeutics and pharmaceutical compositions thereof. These cyclodextrin-containing polymers improve drug stability and solubility, and reduce toxicity of the small molecule therapeutic when used in vivo. Furthermore, by selecting from a variety of linker groups and targeting ligands, the polymers present methods for controlled delivery of the therapeutic agents. The invention also relates to methods for treating subjects with the therapeutic compositions described herein. The invention further relates to methods for conducting pharmaceutical business including manufacturing, licensing, or distributing kits containing or relating to the polymeric compounds described herein.  <P>COPYRIGHT: (C)2011,JPO&INPIT
BACKGROUND: Anthropometry is a reliable method to assess obesity status, and previous studies have shown the association of several dietary quality scores with obesity using anthropometric indices. This study aimed to evaluate the association between LLDS and anthropometric measurements.
METHODS: A total of 217 women between the ages of 18 and 48 participated in the study. Anthropometric values, biochemical tests, and body composition were assessed for each participant using standard protocols and methods. The LLDS was determined based on 12 components using a reliable and valid food frequency questionnaire (FFQ) that contained 147 items.
RESULTS: We detected a marginally significant inverse association between the LLDS and VAI scores in the second tertile. Study participants in the second tertile of LLDS had lower odds of having high VAI than those in the reference tertile after adjusting for age, energy intake, physical activity, education, and economic status (OR: -0.16; 95% CI: -0.8, 0.06; P = 0.06). There was no statistically significant trend for the association between LLDS and all assessed anthropometric indices, including BRI, ABSI, VAI, and BAI, across tertiles of LLDS in the crude and all adjusted models (P-trend > 0.05).
CONCLUSIONS: There was no significant association between LLDS and some novel anthropometric indices, including BRI, ABSI, VAI, and BAI. However, after adjusting for probable confounders, a marginally significant inverse association between LLDS and VAI was detected.
Acute pancreatitis (AP) is a common disease with no targeted therapy and has varied outcomes ranging from spontaneous resolution to being lethal. Although typically painful, AP can also be painless. Various agents, including opioids, are used for pain control in AP; the risks and benefits of which are often debated. As experimental AP in mice is used to study the efficacy of potential therapies, we studied the effect of a commonly used opioid, buprenorphine, on the initiation and progression of AP. For this, we administered extended-release buprenorphine subcutaneously before inducing the previously established severe AP model that uses interleukins 12 and 18 (IL12,18) in genetically obese (ob/ob) mice and compared this to mice with AP but without the drug. Mice were monitored over 3 days, and parameters of AP induction and progression were compared. Buprenorphine significantly reduced serum amylase, lipase, pancreatic necrosis, and AP-associated fat necrosis, which is ubiquitous in obese mice and humans. Buprenorphine delayed the AP-associated reduction of carotid artery pulse distention and the development of hypothermia, hastened renal injury, and muted the early increase in respiratory rate versus IL12,18 alone. The site of buprenorphine injection appeared erythematous, inflamed, and microscopically showed thinning, loss of epidermal layers that had increased apoptosis. In summary, subcutaneous extended-release buprenorphine interfered with the induction of AP by reducing serum amylase, lipase, pancreatic and fat necrosis, the worsening of AP by delaying hypotension, hypothermia, while hastening renal injury, respiratory depression, and causing cutaneous injury at the site of injection.NEW & NOTEWORTHY Extended-release buprenorphine interferes with the initiation and progression of acute pancreatitis at multiple levels.
PURPOSE: To obtain a pharmaceutical composition capable of releasing a drug at a controlled rate over a long period by mixing a polyester-type biodegradable polymer with a natural or synthetic peptide salt in dried state, finely pulverizing the mixture, preliminarily pressing and heating the powder and extruding the product. £ GH-RH, calcitonin, embedding material, endless screw. CONSTITUTION: A biodegradable polymer selected from poly-1,4-butylene succinate, poly-2,3-butylene succinate, poly-1,4-butylene fumarate and poly-2,3- butylene fumarate is mixed with an active component consisting of the pamoate, tannic acid salt, stearic acid salt or palmitic acid salt of a natural or synthetic peptide in dried state until the average size of the produced powder reaches about <500μm. The obtained mixture is preliminarily pressed and heated and then extruded at 90-100 deg.C under a pressure of 50-500kg/cm<2> , the extruded material is cooled and optionally finely pulverized at a low temperature and the powder is classified. The above peptide is e.g. LH-RH and somatostatin.
Aging is a natural process associated with chronic inflammation in the development of vascular dysfunction. We hypothesized that chemokine C-C motif ligands 4 (CCL4) might play a vital role in aging-related vascular dysfunction. Circulating CCL4 was up-regulated in elderly subjects and in aged animals. CCL4 inhibition reduced generation of reactive oxygen species (ROS), attenuated inflammation, and restored cell functions in endothelial progenitor cells from elderly subjects and in aged human aortic endothelial cells. CCL4 promoted cell aging, with impaired cell functioning, by activating ROS production and inflammation. CCL4 knockout mice and therapeutic administration of anti-CCL4 neutralizing antibodies exhibited vascular and dermal anti-aging effects, with improved wound healing, via the down-regulation of inflammatory proteins and the activation of angiogenic proteins. Altogether, our findings suggested that CCL4 may contribute to aging-related vascular dysfunction via activating oxidative stress and endothelial inflammation. CCL4 may be a potential therapeutic target for vascular protections during aging.
A diet planning system for patients with chronic diseases, including a nutritional requirement module, a food record module, a diet filtering module, and a diet planning module. The nutritional requirement module is used to store the nutritional data required by patients with chronic diseases. The food record module is used to store food data. The diet filtering module connects the food record module and the nutrition demand module, and provides a menu from the food data based on the nutritional data required by patients with chronic diseases. The diet planning module is connected to the diet filtering module to provide meals to patients with chronic diseases. Thereby, the diet planning system for patients with chronic diseases can provide appropriate diet planning and facilitate chronic disease patients to control their condition through diet.
Polycystic ovary syndrome (PCOS) is a common gynecological endocrine disease with a certain degree of chronic inflammation and abnormal ovarian angiogenesis in reproductive women. Mesenchymal stem cells (MSCs) have potent immunomodulatory properties to regulate ovarian function, while thrombospondin 1 (TSP1) improves the abnormal formation of ovarian vessels. The present study investigated the efficacy of the combined use of adipose-derived mesenchymal stem cells (ADSCs) and TSP1 in PCOS mice. The PCOS model is established using dehydroepiandrosterone (DHEA) by subcutaneous injection. Ovarian apoptosis is assessed using terminal deoxynucleotidyl transferase dUTP nick-end labeling (TUNEL). Real-time quantitative PCR (RT-PCR) and western blotting are used to detect the expression of inflammatory factors and the levels of angiogenesis-related factors in ovarian tissues. Inflammatory cells count and ovarian angiogenesis are evaluated by immunofluorescence staining. This research shows that TSP1 and ADSCs treatment can significantly reduce the inflammatory state of PCOS mice, relieve the degree of ovarian cell apoptosis, optimize the ovarian histological manifestations, and restore the levels of related hormones. The proportion of CD31-positive cells in PCOS mice returned to near-normal levels. The synergistic use of ADSCs and TSP1 therapy can exert a more impressive effect by inhibiting the ovarian inflammatory response and regulating the balance of angiogenesis than the single application in PCOS mice.
The well-known drug colchicine with various approved therapeutic properties in systemic and topical diseases could be chosen to be formulated in a nanofiberous based drug delivery system that it may enhance the potency and also it reduces the systemic toxicity in local administrations. In this invention, colchicine loaded chitosan based nanofiberous system was formulated, optimized, fully characterized, and evaluated in ex vivo. The optimizations was analyzed via AFM and SEM based on the morphology, topology and the diameters of the nanofibers. In addition, FTIR, XRD, STA, water angle measurement, tensile evaluation, and ex vivo skin permeation were checked. The nanofibers provided a significant colchicine deposition and a notable first order release kinetic behavior. This makes it a formulation to be administered for topical drug delivery or local reservoir for neoadjuvant therapy applying the anticancer property of colchicine, and also as a transdermal colchicine patches.
In recent years, overwhelming evidence has emphasized the crucial role of inflammation in the pathogenesis of PD. However, the exact mechanisms by which inflammation damages dopaminergic neurons in PD are still unclear. Therefore, we generated a MPTP-induced PD mouse model and performed spatial transcriptomic sequencing to provide more insight into the process of PD development at specific brain regions. Our results indicate that the pathological changes of PD are mainly manifested in the midbrain, especially in the substantia nigra region, with significant reductions in oligodendrocytes and Agt-labeled astrocytes and an increase in Gfap-labeled astrocytes. Macrophages displayed an increasing trend in the PD environment, indicating a pattern of immune modulation induced by PD. Moreover, pathway analysis revealed significant impairments in ion migration ability, abnormal Ca2+ channels, cAMP signaling, and synaptic damage in PD. Significant downregulation of Mt1 and Mt2 and upregulation of Atp1b2, Gpi1, and Cox6a1 in PD further underscored the occurrence of intense inflammation and immune alterations. On the basis of these findings, we have validated the significant accumulation of Ca2+ in the midbrain tissue in the PD environment by measuring its content. Additionally, we have demonstrated a close association between the reduction of dopaminergic neurons, represented by the midbrain region, and ferroptosis by evaluating the iron content, malondialdehyde (MDA) levels, and the protein expression of GPX4 and TH in the tissue. We propose the hypothesis that PD-related inflammation and immune changes can induce neuronal and oligodendrocyte damage through the induction of ferroptosis, thereby further accelerating the progression of PD.
Vaccines that elicit broadly protective anti-influenza antibodies. Some vaccines comprise nanoparticles that display HA trimers from influenza virus on their surface. The nanoparticles are fusion proteins comprising a monomeric subunit (e.g., ferritin) joined to the stem region of an influenza HA protein. The fusion proteins self-assemble to form the HA-displaying nanoparticles. The vaccines comprise only the stem region of an influenza HA protein joined to a trimerization domain. Also provided are fusion proteins, and nucleic acid molecules encoding such proteins, and assays using nanoparticles of the invention to detect anti-influenza antibodies.